Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers
NCT01204112
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Interventions
DRUG:
Tasocitinib (CP-690,550) plus Rifampin
Sponsor
Pfizer